Pharmaceutical Industry Clamps Down On Counterfeit Drugs
This article was originally published in PharmAsia News
A conference was held on Jan. 22 to 25 in Guangzhou, China, to rally the pharmaceutical industry to crackdown on counterfeit drugs. According to the China Association for Technical Supervision Information, the national consortium for anti-counterfeit pharmaceuticals worked with authorities in 2007 to investigate more than 120 fake products and 30 infringement rights cases. Counterfeit drugs accounted for 60 percent of the cases investigated, while two-thirds were infringement cases. Counterfeiters have been duplicating and selling branded drugs despite China's crackdown on counterfeiting. As the activity causes business losses and poses a serious threat to public health, experts exhort the industry to assume more responsibilities and actions to deter such incidents. (Click here for more - Chinese Language)
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.